The short version
- Why people research itLean-mass support, recovery, sleep depth, connective-tissue repair and improved body composition via the GH/IGF-1 axis.
- What the evidence isFDA-approved (mecasermin) for severe primary IGF-1 deficiency.
- What to watchSeizure or loss of consciousness from low glucose.
How Increlex works
The single most important fact about injected IGF-1 is not what it does. It is what is missing alongside it.
Mecasermin is recombinant human IGF-1 with no binding protein. Injected on its own, it enters a system whose buffering capacity is already occupied — and in severe primary IGF-1 deficiency, where GH signaling is absent, IGFBP-3 and the acid-labile subunit are themselves low, so the buffer barely exists. The result is a much larger free fraction than the same nominal IGF-1 concentration would produce physiologically.
This is the endpoint delivered directly, which removes the liver's regulatory step and the negative feedback that comes with it.
- Injectable
Where to get Increlex
When a vetted partner does, the link and code go here.
Research on Increlex5 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: FDA-approved (severe primary IGF-1 deficiency); human.
Human clinical evidence
FDA-approved (mecasermin) for severe primary IGF-1 deficiency.
The opposite of how most GH-axis compounds in this Vault are timed.
Correlative data
Long clinical use in a narrow pediatric population. Reported effects include tonsillar hypertrophy and injection-site lipohypertrophy — both consequences of sustained tissue-level IGF-1 rather than surprises.
How the mechanism reads
This is IGF-1 itself, not a secretagogue. Every GHRH analog and ghrelin mimetic in the Vault exists to raise IGF-1; this delivers the endpoint directly and removes the liver's regulatory step along with the negative feedback that comes with it.
MechanisticBypassing that regulation is the entire risk profile in one sentence: there is no upstream brake left.
Mechanistic
Sources
- Bang P, et al. Frequency and Predictive Factors of Hypoglycemia in Patients Treated With rhIGF-1: Data From the Eu-IGFD Registry. Journal of Clinical Endocrinology and Metabolism 2023 · PMID 37579214
- Ramon-Krauel M, et al. Near-Adult Height Outcomes in Patients Treated With rhIGF-1 for Severe Growth Failure: Real-World IGFD Registry Data. Journal of Clinical Endocrinology and Metabolism 2025 · PMID 40626687
- Backeljauw PF, et al. Challenges in the care of individuals with severe primary insulin-like growth factor-I deficiency (SPIGFD): an international, multi-stakeholder perspective. Orphanet Journal of Rare Diseases 2023 · PMID 37805563
- LeRoith D, et al. Insulin-like growth factors: Ligands, binding proteins, and receptors. Molecular Metabolism 2021 · PMID 33962049
- Fintini D, et al. Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency. Therapeutics and Clinical Risk Management 2009 · PMID 19707272
- Vilmann L, et al. Bioactive Insulin-like Growth Factor (IGF)-I Concentrations in Children on Growth Hormone Therapy. Journal of Clinical Endocrinology and Metabolism 2025 · PMID 41083160
Increlex safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Active or suspected cancer, a labeled contraindication.
- Closed growth plates.
- Intracranial hypertension.
- Benzyl alcohol allergy, since the label formulation contains it.
- Scoliosis, tonsillar hypertrophy or sleep apnea, which can worsen.
What’s expected
- Hypoglycemia, the dose-limiting toxicity, measured at a registry frequency of about one in four patients.
- Injection-site thickening or fat change.
- Tonsil and adenoid enlargement.
Watch for
- Seizure or loss of consciousness from low glucose.
- Headache with vision change.
- Hip or knee pain in a growing child, and new snoring.
Labs that tell you it’s working
- IGF-1: the directly delivered endpoint, which should rise toward normal.
- C-Peptide, Serum: suppressed by IGF-1, showing the insulin-like effect.
- Insulin (Fasting): falls when IGF-1 supplies insulin-like signaling.
- Fructosamine: reads recent glucose swings.
Recombinant human IGF-1 (mecasermin): the endpoint delivered directly, bypassing hepatic regulation; hypoglycemia is the labeled dose-limiting risk. PMID 37579214 PMID 40626687 PMID 37805563
Bloodwork to runHow you would know it is working: 8 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
Increlex FAQ4 common questions
- Is Increlex approved for human use?
- Increlex is an approved medicine for the uses on its label. This page covers research beyond those uses, as education, not medical advice.
- What is Increlex researched for?
- Lean-mass support, recovery, sleep depth, connective-tissue repair and improved body composition via the GH/IGF-1 axis.
- Which labs show whether it's doing anything?
- IGF-1; C-Peptide, Serum; Insulin; Fructosamine: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for Increlex: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



